CO2023002202A2 - Inhibidores de la secreción de proteínas - Google Patents

Inhibidores de la secreción de proteínas

Info

Publication number
CO2023002202A2
CO2023002202A2 CONC2023/0002202A CO2023002202A CO2023002202A2 CO 2023002202 A2 CO2023002202 A2 CO 2023002202A2 CO 2023002202 A CO2023002202 A CO 2023002202A CO 2023002202 A2 CO2023002202 A2 CO 2023002202A2
Authority
CO
Colombia
Prior art keywords
protein secretion
secretion inhibitors
inhibitors
methods
protein
Prior art date
Application number
CONC2023/0002202A
Other languages
English (en)
Inventor
Dustin Mcminn
Meera Rao
Original Assignee
Kezar Life Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kezar Life Sciences filed Critical Kezar Life Sciences
Publication of CO2023002202A2 publication Critical patent/CO2023002202A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

En la presente se proporcionan inhibidores de secreción, tales como inhibidores de Sec61, métodos para su preparación, composiciones farmacéuticas relacionadas y métodos para usarlos.
CONC2023/0002202A 2020-08-31 2023-02-27 Inhibidores de la secreción de proteínas CO2023002202A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063072690P 2020-08-31 2020-08-31
PCT/US2021/048317 WO2022047347A1 (en) 2020-08-31 2021-08-31 Protein secretion inhibitors

Publications (1)

Publication Number Publication Date
CO2023002202A2 true CO2023002202A2 (es) 2023-03-27

Family

ID=78087485

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0002202A CO2023002202A2 (es) 2020-08-31 2023-02-27 Inhibidores de la secreción de proteínas

Country Status (16)

Country Link
US (1) US20230286973A1 (es)
EP (1) EP4204417A1 (es)
JP (1) JP2023539553A (es)
KR (1) KR20230058655A (es)
CN (1) CN116194455A (es)
AR (1) AR123385A1 (es)
AU (1) AU2021334388A1 (es)
BR (1) BR112023003265A2 (es)
CA (1) CA3190441A1 (es)
CL (1) CL2023000582A1 (es)
CO (1) CO2023002202A2 (es)
IL (1) IL300736A (es)
MX (1) MX2023002288A (es)
PE (1) PE20231436A1 (es)
TW (1) TW202227428A (es)
WO (1) WO2022047347A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR128634A1 (es) * 2022-02-28 2024-05-29 Kezar Life Sciences Inhibidores de sec61 y uso de los mismos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6042820A (en) 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US6472375B1 (en) 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
WO2019046668A1 (en) * 2017-08-31 2019-03-07 Kezar Life Sciences AMIDE-SUBSTITUTED THIAZOLES AS INHIBITORS OF SECRETIC PROTEIN
MX2021010314A (es) * 2019-02-28 2021-11-12 Kezar Life Sciences Derivados de tiazol como inhibidores de la secreción de proteínas.

Also Published As

Publication number Publication date
CN116194455A (zh) 2023-05-30
JP2023539553A (ja) 2023-09-15
TW202227428A (zh) 2022-07-16
EP4204417A1 (en) 2023-07-05
US20230286973A1 (en) 2023-09-14
PE20231436A1 (es) 2023-09-14
CA3190441A1 (en) 2022-03-03
KR20230058655A (ko) 2023-05-03
BR112023003265A2 (pt) 2023-05-02
IL300736A (en) 2023-04-01
AR123385A1 (es) 2022-11-23
WO2022047347A1 (en) 2022-03-03
CL2023000582A1 (es) 2023-09-29
MX2023002288A (es) 2023-03-10
AU2021334388A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
CO2021012176A2 (es) Preparaciones de membrana bacteriana
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
BR112019018685A8 (pt) Anticorpos, composição farmacêutica, kit, usos de um anticorpo e método in vitro de identificação ou seleção de um anticorpo
BR112021017049A2 (pt) Derivados de tiazol como inibidores de secreção de proteínas
EA201890817A1 (ru) Кристаллические формы бета-никотинамида мононуклеотида
CO2017004714A2 (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
CR20140586A (es) Celulas para producir iduronato-2-sulfatasa recombinante
UY34578A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas q ue los contienen
BR112015001528A2 (pt) Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
BR112019025388A2 (pt) Suplemento de ração animal, composição de ração animal, usos de um suplemento de ração animal, métodos para produzir um suplemento de ração animal e para produzir uma composição de ração animal
CO2023002202A2 (es) Inhibidores de la secreción de proteínas
BR112017023780A2 (pt) sulfonas tricíclicas como moduladores de rorgama
CO2020007044A2 (es) Derivados de pirrol como inhibidores de acc
ECSP20063338A (es) Suplemento de cutícula para producción vegetal
CO2021018181A2 (es) Composiciones de proteína anti-vegf y métodos para producir la misma
BR112018071592A2 (pt) inibidores de erbb e usos dos mesmos
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
UY37611A (es) Formulaciones de evolocumab de alta concentración y baja viscosidad y métodos para elaborarlas
CL2021002182A1 (es) Formulación de anticuerpos terapéuticos
AR115359A1 (es) Preparaciones microbianas para plantas, composiciones y formulaciones que las comprenden y sus usos
CL2012000013A1 (es) Compuestos derivados de 4-{3-[3-(4-trifluorometil-fenil)ureido]-5-fluoro-bencilamino}-1h-pirazol-3-carboxamida; procedimiento de preparacion; composicion farmaceutica que los comprende; compuestos intermediarios; y su uso como moduladores de la actividad de las proteinas quinasa para el tratamiento del cancer.
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
EA202191403A1 (ru) Композиция с высокой концентрацией белка
CO2019013557A2 (es) Compuestos
CO2020012484A2 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")